Summary of Study ST002355
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001512. The data can be accessed directly via it's Project DOI: 10.21228/M8812G This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
Study ID | ST002355 |
Study Title | Stool short chain fatty acid (SCFA) levels in peanut allergy |
Study Summary | Prior evidence supports differential levels of short chain fatty acids in the stool of human beings with allergy and murine models of allergy. Here we performed a targeted study of selected short chain fatty acid levels in stool samples collected from children with allergy risk factors. Sample processing included homogenization of stool samples, inclusion of internal standards, and derivitization for liquid chromatography tandem mass spectrometry. |
Institute | Icahn School of Medicine at Mount Sinai |
Last Name | Bunyavanich |
First Name | Supinda |
Address | 1 Gustave L. Levy Pl, New York, NY 10029 |
supinda.bunyavanich@mssm.edu | |
Phone | Stool metabolite levels in individuals with peanut allergy were measured. |
Submit Date | 2022-11-08 |
Raw Data Available | Yes |
Raw Data File Type(s) | mzXML |
Analysis Type Detail | LC-MS |
Release Date | 2023-12-08 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR002456 |
Treatment Summary: | Children were categorized as PA if they developed peanut allergy by mid-childhood and not peanut allergic (NPA) if they did not develop peanut allergy by mid-childhood. In study design table, subjects were sampled in infancy and then again mid childhood and placed into either PA or NPA for the purpose of this study. Peanut allergy was defined based on: (1) confirmed IgE-mediated reaction (e.g. positive doctor supervised oral food challenge to peanut and sensitization to peanut), or (2) convincing IgEmediated reaction (e.g. convincing reaction and sensitization to peanut) at any visit.16 This was “alternate definition 1” of the parent CoFAR2 study16 . We used this definition rather than the main definition to avoid inclusion of less convincing peanut allergy in case ascertainment, as the main definition16 also included those with peanut sensitization but no history of reaction. |